GlassScriptPhysician profile
Raphael Arturo Palacios
NPI 1407462385
$16,178.33
in general payments reported to CMS, 2019-2025
32 companies · $4,568 in 2025
The $4,568 reported for 2025 was more than what 98% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,840 · 2022: $3,227 · 2023: $3,823 · 2024: $2,720 · 2025: $4,568.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $6.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,104.43 |
| Education | $6.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,093.33 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,573.58 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $1,541.54 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $1,286.51 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Janssen Pharmaceuticals, INC | $1,158.33 | 2021-2025 | Spravato, Invega Sustenna |
| Vanda Pharmaceuticals INC. | $1,079.97 | 2021-2025 | Fanapt, Hetlioz |
| Neurocrine Biosciences, INC. | $1,065.39 | 2022-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $843.33 | 2022-2025 | Auvelity |
| Indivior INC. | $788.88 | 2021-2025 | Sublocade, Perseris |
| Takeda Pharmaceuticals U.S.A., INC. | $778.51 | 2021-2025 | Trintellix |
| Alkermes, INC. | $695.32 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Almatica Pharma LLC | $668.51 | 2021-2025 | Loreev Xr, Sertraline Hcl |
| Corium, LLC | $603.84 | 2022-2024 | Azstarys |
| Bausch Health US, LLC | $371.48 | 2022-2025 | Aplenzin, Wellbutrin |
| Sunovion Pharmaceuticals INC. | $345.36 | 2021-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $303.53 | 2022-2024 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $219.21 | 2025 | Cobenfy |
| Lundbeck LLC | $199.39 | 2024-2025 | Rexulti |
| Braeburn INC. | $148.50 | 2025 | Brixadi |
| Ironshore Pharmaceuticals INC. | $79.05 | 2022-2024 | Jornay Pm |
| Orexo US, INC. | $77.39 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $48.32 | 2023 | Qelbree |
| Merck Sharp & Dohme LLC | $33.67 | 2023 | Belsomra |
| Luye Pharma (USA) LTD. | $23.54 | 2025 | Erzofri Extended-Release |
| Acadia Pharmaceuticals INC | $23.38 | 2023 | Nuplazid |
| Noven Therapeutics, LLC | $21.16 | 2021 | |
| Tris Pharma INC | $19.48 | 2025 | Dyanavel Xr |
| Eisai INC. | $19.19 | 2021 | |
| Jazz Pharmaceuticals INC. | $18.93 | 2021 | |
| Alfasigma USA, INC. | $17.96 | 2022 | |
| Adlon Therapeutics L.P. | $16.86 | 2021 | |
| Collegium Pharmaceutical, INC. | $14.89 | 2025 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raphael Palacios listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.